Cargando…

Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample

In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm....

Descripción completa

Detalles Bibliográficos
Autores principales: Boissel, Jean-Pierre, Pérol, David, Décousus, Hervé, Klingmann, Ingrid, Hommel, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504716/
https://www.ncbi.nlm.nih.gov/pubmed/34634062
http://dx.doi.org/10.1371/journal.pone.0258093
_version_ 1784581374564368384
author Boissel, Jean-Pierre
Pérol, David
Décousus, Hervé
Klingmann, Ingrid
Hommel, Marc
author_facet Boissel, Jean-Pierre
Pérol, David
Décousus, Hervé
Klingmann, Ingrid
Hommel, Marc
author_sort Boissel, Jean-Pierre
collection PubMed
description In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm. RCTs emerged mid-last century as the gold standard for assessing efficacy, becoming the cornerstone of the value of new therapies, yet their ethical grounds are a matter of debate. We introduce the concept of unnecessary participants in RCTs, the sum of non-informative participants and non-responders. The non-informative participants are considered not informative with respect to the efficacy measured in the trial in contrast to responders who carry all the information required to conclude on the treatment’s efficacy. The non-responders present the event whether or not they are treated with the experimental treatment. The unnecessary participants carry the burden of having to participate in a clinical trial without benefiting from it, which might include experiencing side effects. Thus, these unnecessary participants carry the ethical loss that is inherent to the RCT methodology. On the contrary, responders to the experimental treatment bear its entire efficacy in the RCT. Starting from the proportions observed in a real placebo-controlled trial from the literature, we carried out simulations of RCTs progressively increasing the proportion of responders up to 100%. We show that the number of unnecessary participants decreases steadily until the RCT’s ethical loss reaches a minimum. In parallel, the trial sample size decreases (presumably its cost as well), although the trial’s statistical power increases as shown by the increase of the chi-square comparing the event rates between the two arms. Thus, we expect that increasing the proportion of responders in RCTs would contribute to making them more ethically acceptable, with less false negative outcomes.
format Online
Article
Text
id pubmed-8504716
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85047162021-10-12 Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample Boissel, Jean-Pierre Pérol, David Décousus, Hervé Klingmann, Ingrid Hommel, Marc PLoS One Research Article In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm. RCTs emerged mid-last century as the gold standard for assessing efficacy, becoming the cornerstone of the value of new therapies, yet their ethical grounds are a matter of debate. We introduce the concept of unnecessary participants in RCTs, the sum of non-informative participants and non-responders. The non-informative participants are considered not informative with respect to the efficacy measured in the trial in contrast to responders who carry all the information required to conclude on the treatment’s efficacy. The non-responders present the event whether or not they are treated with the experimental treatment. The unnecessary participants carry the burden of having to participate in a clinical trial without benefiting from it, which might include experiencing side effects. Thus, these unnecessary participants carry the ethical loss that is inherent to the RCT methodology. On the contrary, responders to the experimental treatment bear its entire efficacy in the RCT. Starting from the proportions observed in a real placebo-controlled trial from the literature, we carried out simulations of RCTs progressively increasing the proportion of responders up to 100%. We show that the number of unnecessary participants decreases steadily until the RCT’s ethical loss reaches a minimum. In parallel, the trial sample size decreases (presumably its cost as well), although the trial’s statistical power increases as shown by the increase of the chi-square comparing the event rates between the two arms. Thus, we expect that increasing the proportion of responders in RCTs would contribute to making them more ethically acceptable, with less false negative outcomes. Public Library of Science 2021-10-11 /pmc/articles/PMC8504716/ /pubmed/34634062 http://dx.doi.org/10.1371/journal.pone.0258093 Text en © 2021 Boissel et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Boissel, Jean-Pierre
Pérol, David
Décousus, Hervé
Klingmann, Ingrid
Hommel, Marc
Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
title Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
title_full Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
title_fullStr Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
title_full_unstemmed Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
title_short Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
title_sort using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504716/
https://www.ncbi.nlm.nih.gov/pubmed/34634062
http://dx.doi.org/10.1371/journal.pone.0258093
work_keys_str_mv AT boisseljeanpierre usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample
AT peroldavid usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample
AT decoususherve usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample
AT klingmanningrid usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample
AT hommelmarc usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample